national stem-cell therapy logo

ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers

ExCellThera

MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy, ExCellThera’s most advanced investigational drug, combines the proprietary molecule UM171 and an […]

ExCellThera announces 100th patient treated with UM171-expanded cell therapy

ExCellThera

MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological […]